Roche Agrees To Court Conditions For Mircera Launch
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.